US FDA’s 30-Day Extension For Nitrosamine Assessments Short Of Industry Recommendation
Executive Summary
Revision to FDA's September 2020 guidance on assessing nitrosamine impurity risks associated with all chemically synthesized APIs and all approved drug products that contain those APIs doesn’t satisfy industry stakeholders.
You may also be interested in...
Hand Sanitizers Raise OTC Profile In US FDA’s Latest Drug Manufacturing Quality Report
Widespread problems FDA found in hand sanitizers resulted from businesses unfamiliar with drug production entering the space after agency eased manufacturing standards to encourage increased supplies. Heartburn remedy ranitidine noted due to its chemical profile, not errors by manufacturers.
US FDA Won't Budge On Nitrosamines Compliance Despite Complaints Of Possible Drug Shortages
Industry requests for deadline extensions, short-duration adjustments and other accommodations go nowhere as FDA expresses concerns about nitrosamines’ mutagenic potency.
Perrigo Among Firms Requesting Delay In Conducting US Nitrosamine Risk Assessments
Perrigo, Pfizer want FDA to postpone its March deadline for conducting nitrosamine risk assessments. Generics executive cites “serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.